Olympus Launches CT-Based AI Software for Emphysema Screening
Through AI assessment of chest CT scans, the SeleCT Screening may help identify candidates for bronchoscopic lung volume reduction to improve lung function.
A new computed tomography (CT)-based artificial intelligence (AI) software may facilitate more timely detection of emphysema.
The SeleCT™ Screening software utilizes AI to help detect severe emphysema in patients, who may be viable candidates for minimally invasive bronchoscopic lung volume reduction (BLVR), according to Olympus, the developer of the SeleCT Screening software.
For people with emphysema, the AI-powered SeleCT Screening software could help identify potential candidates for minimally invasive bronchoscopic lung volume reduction (BLVR), according to Olympus, the developer of the software. (Image courtesy of Adobe Stock.)
Noting that emphysema has been diagnosed in more than three million people in the United States and that up to 80 percent of patients with chronic obstructive pulmonary disease (COPD) are underdiagnosed, Olympus said the SeleCT Screening software can lead to improved detection and timely intervention to bolster lung function.
"Emphysema can have a debilitating effect on a person's life. Bronchoscopic lung volume reduction is a way to help those dealing with the disease to reclaim some of the freedoms they may have lost," said Kyle Hogarth, M.D., a professor medicine and director of bronchoscopy at the University of Chicago. "Technology like SeleCT Screening is an effective way to more quickly identify those who could most benefit from treatment and experience an improved quality of life."
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Chest CT for Post-COVID-19 Abnormalities: Nine Takeaways from a Multi-Society Consensus Statement
July 22nd 2025Developed by 21 thoracic radiologists, the new international consensus statement addresses appropriate indications, scan acquisition and keys to reporting for the use of chest CT imaging in evaluating for residual lung abnormalities from COVID-19.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.
Stroke MRI Study Assesses Impact of Motion Artifacts Upon AI and Radiologist Lesion Detection
July 16th 2025Noting a 7.4 percent incidence of motion artifacts on brain MRI scans for suspected stroke patients, the authors of a new study found that motion artifacts can reduce radiologist and AI accuracy for detecting hemorrhagic lesions.
